← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Cogent Biosciences, Inc. (COGT) 10-Year Financial Performance & Capital Metrics

COGT •
HealthcareBiotechnologyCommercial Rare Disease Biopharma
AboutCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more
  • Revenue $0
  • EBITDA -$329M -21.0%
  • Net Income -$329M -28.6%
  • EPS (Diluted) -2.55 -3.7%
  • Gross Margin -
  • EBITDA Margin -
  • Operating Margin -
  • Net Margin -
  • ROE -73.7% +26.0%
  • ROIC -66.4% +36.0%
  • Debt/Equity 0.40 +483.7%
  • Interest Coverage -108.87
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 97 (top 3%)
  • ✓Share count reduced 34.9% through buybacks

✗Weaknesses

  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-28.56%

EPS CAGR

10Y-
5Y-
3Y-
TTM-4.06%

ROCE

10Y Avg-60.23%
5Y Avg-65.72%
3Y Avg-78.26%
Latest-58.19%

Peer Comparison

Commercial Rare Disease Biopharma
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CORTCorcept Therapeutics Incorporated3.78B35.7043.5412.79%13.01%15.3%3.75%0.01
BMRNBioMarin Pharmaceutical Inc.11.86B61.7334.2910.83%5.73%6.11%0.10
VRTXVertex Pharmaceuticals Incorporated126.19B496.8332.438.9%31.35%21.22%2.53%0.20
CPRXCatalyst Pharmaceuticals, Inc.2.83B23.0813.7419.78%36.39%22.46%7.38%0.00
HRMYHarmony Biosciences Holdings, Inc.1.65B28.5410.5321.51%18.27%18.24%21.12%0.02
PTCTPTC Therapeutics, Inc.5.45B68.198.76114.51%42.25%
BCRXBioCryst Pharmaceuticals, Inc.1.86B8.757.2394.1%30.16%18.63%
RAREUltragenyx Pharmaceutical Inc.2.26B23.39-3.7229.01%-91.95%-35.88%0.15

Compare COGT vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs AGIO

Compare head-to-head with Agios Pharmaceuticals, Inc.

vs VRTX

Compare head-to-head with Vertex Pharmaceuticals Incorporated

Compare Top 5

vs AGIO, VRTX, ASND, BBIO

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+6.36M8.36M9.73M22.5M7.87M00000
Revenue Growth %112.83%31.55%16.44%131.14%-65.02%-100%----
Cost of Goods Sold+00043.71K25.74M00004.62M
COGS % of Revenue---0.19%327%-----
Gross Profit+6.36M8.36M9.73M22.46M-17.87M0000-4.62M
Gross Margin %100%100%100%99.81%-227%-----
Gross Profit Growth %112.83%31.55%16.44%130.69%-179.57%100%----
Operating Expenses+25.43M34.51M45.74M54.68M64.33M75.55M147.84M208.13M275.94M328.74M
OpEx % of Revenue400.08%412.82%469.89%243.02%817.33%-----
Selling, General & Admin3.43M4.68M7.45M10.97M17.42M19.64M26.21M34.38M43.28M63.58M
SG&A % of Revenue54.02%55.98%76.58%48.75%221.34%-----
Research & Development21.99M29.83M38.28M43.71M72.65M55.91M121.63M173.75M232.66M269.78M
R&D % of Revenue346.06%356.84%393.31%194.27%922.98%-----
Other Operating Expenses0274K320K78K-25.74M0000-4.62M
Operating Income+-19.07M-26.15M-36.01M-32.18M-82.2M-75.55M-147.84M-208.13M-275.94M-333.36M
Operating Margin %-300.08%-312.82%-369.89%-143.02%-1044.33%-----
Operating Income Growth %-189.29%-37.14%-37.68%10.63%-155.45%8.09%-95.68%-40.78%-32.58%-20.81%
EBITDA+-18.24M-24.98M-34.68M-30.89M-81.48M-73.56M-141.96M-204.54M-271.59M-328.74M
EBITDA Margin %-287.02%-298.82%-356.32%-137.27%-1035.18%-----
EBITDA Growth %-184.42%-36.96%-38.84%10.95%-163.81%9.72%-92.99%-44.08%-32.78%-21.05%
D&A (Non-Cash Add-back)830K1.17M1.32M1.29M720K1.99M5.88M3.59M4.35M4.62M
EBIT-19.07M-26.15M-36.01M-32.18M-35.29M-75.55M-147.84M-208.13M-275.94M-333.36M
Net Interest Income+265K386K1.15M267K144K467K013.08M18.09M11.63M
Interest Income265K386K1.15M267K144K467K3.99M13.08M18.09M14.69M
Interest Expense0000003.99M003.06M
Other Income/Expense946K660K1.47M345K7.39M3.28M7.6M15.72M20.08M4.43M
Pretax Income+-18.12M-25.49M-34.53M-31.83M-74.81M-72.27M-140.24M-192.41M-255.86M-328.94M
Pretax Margin %-285.19%-304.93%-354.76%-141.49%-950.43%-----
Income Tax+0000000000
Effective Tax Rate %100%100%100%95.1%100%100%100%100%100%100%
Net Income+-18.12M-25.49M-34.53M-30.27M-74.81M-72.27M-140.24M-192.41M-255.86M-328.94M
Net Margin %-285.19%-304.93%-354.76%-134.55%-950.43%-----
Net Income Growth %-174.94%-40.65%-35.46%12.33%-147.11%3.39%-94.04%-37.2%-32.98%-28.56%
Net Income (Continuing)-18.12M-25.49M-34.53M-31.83M-74.81M-72.27M-140.24M-192.41M-255.86M-328.94M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-2.45-3.45-5.55-3.97-6.00-1.85-2.26-2.42-2.46-2.55
EPS Growth %-175.28%-40.82%-60.87%28.47%-51.13%69.17%-22.16%-7.08%-1.65%-3.66%
EPS (Basic)-3.10-3.45-5.55-3.97-6.00-1.85-2.26-2.42-2.46-2.55
Diluted Shares Outstanding7.4M7.4M6.22M7.62M11.08M38.73M58.74M79.66M103.86M67.6M
Basic Shares Outstanding5.86M7.4M6.22M7.62M11.08M38.73M58.74M79.66M103.86M67.6M
Dividend Payout Ratio----------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+69.73M42.38M81M40.59M244.91M222.63M264.97M270.77M296.47M910.36M
Cash & Short-Term Investments68.51M40.96M78.59M37.42M242.19M219.68M259.28M265.71M287.08M900.76M
Cash Only41.32M28.27M55.67M37.42M242.19M219.68M139.89M53.23M98.17M312.01M
Short-Term Investments27.19M12.69M22.92M000119.39M212.48M188.91M588.75M
Accounts Receivable928K830K1.67M2M000000
Days Sales Outstanding53.336.2462.5532.45------
Inventory075K00000000
Days Inventory Outstanding----------
Other Current Assets075K740K0001.25M5.06M9.39M9.59M
Total Non-Current Assets+5.82M6.74M4.92M8.83M6M9.46M35.84M42.67M31.43M27.25M
Property, Plant & Equipment4.56M4.11M3.25M7.15M4.75M4.48M31.1M30.34M26.56M23.54M
Fixed Asset Turnover1.39x2.04x2.99x3.15x1.66x-----
Goodwill0000000000
Intangible Assets0000000000
Long-Term Investments1.25M1.25M1.25M00007.46M00
Other Non-Current Assets01.37M419K1.68M1.25M4.98M4.75M4.86M4.86M3.72M
Total Assets+75.55M49.12M85.93M49.42M250.92M232.09M300.81M313.44M327.9M937.61M
Asset Turnover0.08x0.17x0.11x0.46x0.03x-----
Asset Growth %-20.28%-34.99%74.95%-42.48%407.69%-7.5%29.61%4.2%4.61%185.94%
Total Current Liabilities+8.74M11.19M24.95M13.25M13.09M17.08M26.85M38.17M55.71M63.95M
Accounts Payable1.45M1.35M1.52M3.18M732K3.48M5.84M10.65M12.01M9.5M
Days Payables Outstanding---26.58K10.38----751.02
Short-Term Debt0000000001.55M
Deferred Revenue (Current)5.96M6.89M17.95M1.31M03.06M1.7M000
Other Current Liabilities118K1.64M3.88M3.39M7.28M3.62M6.47M10.31M12.63M52.9M
Current Ratio7.98x3.79x3.25x3.06x18.70x13.04x9.87x7.09x5.32x14.23x
Quick Ratio7.98x3.78x3.25x3.06x18.70x13.04x9.87x7.09x5.32x14.23x
Cash Conversion Cycle----------
Total Non-Current Liabilities+14.43M9.62M748K4.41M3.15M831K18.23M17.47M15.9M237.28M
Long-Term Debt000000000237.25M
Capital Lease Obligations0004.41M3.15M831K18.23M17.47M15.9M14.36M
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities908K906K748K000000-14.32M
Total Liabilities23.16M20.81M25.69M17.66M16.25M17.91M45.08M55.63M71.61M301.24M
Total Debt+0006.03M5.21M3.15M19.65M18.85M17.47M253.15M
Net Debt-41.32M-28.27M-55.67M-31.39M-236.98M-216.53M-120.24M-34.38M-80.7M-58.86M
Debt / Equity---0.19x0.02x0.01x0.08x0.07x0.07x0.40x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-------37.06x---108.87x
Total Equity+52.39M28.3M60.23M31.76M234.67M214.18M255.74M257.8M256.29M636.37M
Equity Growth %-24.64%-45.97%112.8%-47.27%638.83%-8.73%19.4%0.81%-0.59%148.31%
Book Value per Share7.083.839.684.1721.185.534.353.242.479.41
Total Shareholders' Equity52.39M28.3M60.23M31.76M234.67M214.18M255.74M257.8M256.29M636.37M
Common Stock10K10K30K8K32K44K70K86K110K161K
Retained Earnings-25.85M-51.34M-92.06M-123.89M-198.7M-270.97M-411.21M-603.62M-859.48M-1.19B
Treasury Stock0000000000
Accumulated OCI-24K-16K-12K000-104K246K447K355K
Minority Interest0000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+-18.64M-25.84M-32.49M-41.51M-35.85M-58.76M-118.64M-153.62M-207.79M-264.44M
Operating CF Margin %-293.31%-309.03%-333.77%-184.51%-455.47%-----
Operating CF Growth %-205.22%-38.6%-25.76%-27.78%13.64%-63.91%-101.89%-29.49%-35.26%-27.26%
Net Income-18.12M-25.49M-34.53M-31.83M-74.81M-72.27M-140.24M-192.41M-255.86M-328.94M
Depreciation & Amortization830K1.17M1.32M1.29M720K147K5.88M3.59M4.35M4.58M
Stock-Based Compensation1.02M1.34M3.09M3.24M6.02M11.69M18.37M30.62M39.74M46.08M
Deferred Taxes17K17K-236K0000000
Other Non-Cash Items-56K7K23K-131K37.54M-343K-3.39M-6.87M-7.62M5.82M
Working Capital Changes-2.32M-2.88M-2.15M-14.08M-5.32M2.02M751K11.44M11.6M8.01M
Change in Receivables-634K98K-838K-332K2M00000
Change in Inventory784K931K2.21M0000000
Change in Payables389K-31K367K1.66M-2.45M2.75M2.36M4.81M1.36M-2.51M
Cash from Investing+-30.43M13.51M-10.53M23.16M8.42M-1.72M-124.72M-97.82M38.28M-399.53M
Capital Expenditures-3.31M-912K-549K-33K0-1.72M-6.86M-2.8M-573K-1.55M
CapEx % of Revenue52.04%10.91%5.64%0.15%------
Acquisitions000204K00117.86K000
Investments----------
Other Investing50K-75K008.42M0-117.86K000
Cash from Financing+-40K-729K70.35M108K232.2M37.98M163.56M163.54M214.45M878.23M
Debt Issued (Net)000000000215.13M
Equity Issued (Net)060K1000K108K1000K1000K1000K1000K1000K1000K
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing-40K-789K-1.45M0560K-30K1.61M01.11M-48.9M
Net Change in Cash-49.11M-13.05M27.33M-18.25M204.77M-22.51M-79.8M-87.91M44.94M214.26M
Free Cash Flow+-21.95M-26.75M-33.04M-41.55M-35.85M-60.48M-125.5M-156.42M-208.36M-266M
FCF Margin %-345.35%-319.94%-339.41%-184.66%-455.47%-----
FCF Growth %-239.59%-21.87%-23.52%-25.76%13.71%-68.71%-107.5%-24.64%-33.21%-27.66%
FCF per Share-2.97-3.62-5.31-5.45-3.24-1.56-2.14-1.96-2.01-3.93
FCF Conversion (FCF/Net Income)1.03x1.01x0.94x1.37x0.48x0.81x0.85x0.80x0.81x0.80x
Interest Paid0000000000
Taxes Paid0000000000

Key Ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-29.73%-63.18%-78%-65.81%-56.16%-32.2%-59.69%-74.94%-99.54%-73.7%
Return on Invested Capital (ROIC)--353.34%-1174.59%-978.45%---166.54%-86.98%-103.73%-66.4%
Gross Margin100%100%100%99.81%-227%-----
Net Margin-285.19%-304.93%-354.76%-134.55%-950.43%-----
Debt / Equity---0.19x0.02x0.01x0.08x0.07x0.07x0.40x
Interest Coverage-------37.06x---108.87x
FCF Conversion1.03x1.01x0.94x1.37x0.48x0.81x0.85x0.80x0.81x0.80x
Revenue Growth112.83%31.55%16.44%131.14%-65.02%-100%----

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.